Effect of Oral Ranitidine on Urinary Excretion of<i>N</i>-Nitrosodimethylamine (NDMA)
Jeffry Florian(United States Food and Drug Administration), David G. Strauss(Center for Drug Evaluation and Research), Liang Zhao(United States Food and Drug Administration), Susan Selaya(United States Food and Drug Administration), Victoria Gershuny(United States Food and Drug Administration), Murali K. Matta(United States Food and Drug Administration), Rodney Rouse(United States Food and Drug Administration), Kristin Prentice, In‐Sook Kim(Frederick National Laboratory for Cancer Research), Ryan DePalma(United States Food and Drug Administration), Robbert Zusterzeel(United States Food and Drug Administration), Joyce A. Korvick(United States Food and Drug Administration), SoJeong Yi(United States Food and Drug Administration), Colleen Gosa Nalepinski(Spaulding Clinical Research (United States)), Miyoung Yoon(The Hamner Institutes for Health Sciences), Cheng‐Hui Hsiao(University of Houston), Vikram Patel(United States Food and Drug Administration), David A. Keire(Center for Drug Evaluation and Research)
Cited by 30
Related Papers
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
|Journal of Lipid Research|2007|595
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
|Clinical Cancer Research|2015|377
Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
|Carcinogenesis|2006|359
DYRK1A-mediated Hyperphosphorylation of Tau
|Journal of Biological Chemistry|2007|273